Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Embeda Uptake In Primary Care Depends On FDA Clearing Marketing Materials, King Says

This article was originally published in The Pink Sheet Daily

Executive Summary

After a warning letter, Embeda sales effort focuses on specialists. Firm does not see franchise threat from generics, although Remoxy will not be refiled until the middle of next year.

You may also be interested in...



King Assures Investors Embeda Marketing Materials Not Lost In DDMAC "Black Hole"

Five months after the launch of King's oral morphine Embeda, execs still await FDA approval of marketing materials.

King Assures Investors Embeda Marketing Materials Not Lost In DDMAC "Black Hole"

Five months after the launch of King's oral morphine Embeda, execs still await FDA approval of marketing materials.

King Expects Acurox Committee In April: What Are The Standards For Aversion-Based Abuse-Resistance?

King Pharmaceuticals expects up-or-down vote on formulation of immediate-release oxycodone with niacin. King will resubmit Acurox application after meeting.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068831

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel